Daewon Pharmaceutical Co (XKRX:003220) Total Liabilities : ₩298,811 Mil (As of Dec. 2024)

View and export this data going back to 1999. Start your Free Trial

What is Daewon Pharmaceutical Co Total Liabilities?

Daewon Pharmaceutical Co's Total Liabilities for the quarter that ended in Dec. 2024 was ₩298,811 Mil.

Daewon Pharmaceutical Co's quarterly Total Liabilities increased from Jun. 2024 (₩302,861.39 Mil) to Sep. 2024 (₩308,981.32 Mil) but then declined from Sep. 2024 (₩308,981.32 Mil) to Dec. 2024 (₩298,810.60 Mil).

Daewon Pharmaceutical Co's annual Total Liabilities increased from Dec. 2022 (₩204,784.87 Mil) to Dec. 2023 (₩243,733.87 Mil) and increased from Dec. 2023 (₩243,733.87 Mil) to Dec. 2024 (₩298,810.60 Mil).

Daewon Pharmaceutical Co Total Liabilities Historical Data

The historical data trend for Daewon Pharmaceutical Co's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Daewon Pharmaceutical Co Total Liabilities Chart

Daewon Pharmaceutical Co Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Liabilities

Get a 7-Day Free Trial

122,442.34

211,176.23

204,784.87

243,733.87

298,810.60

Daewon Pharmaceutical Co Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Total Liabilities	Get a 7-Day Free Trial															243,733.87	278,217.03	302,861.39	308,981.32	298,810.60

Daewon Pharmaceutical Co Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Daewon Pharmaceutical Co's Total Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	200776.167	+	(66488.971	+	3656.203
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	27792.135	+	97.12)
	=	298,811

Total Liabilities	=	Total Assets (A: Dec. 2024 )	-	Total Equity (A: Dec. 2024 )
	=	583388.834	-	284578.238
	=	298,811

Daewon Pharmaceutical Co's Total Liabilities for the quarter that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	200776.167	+	(66488.971	+	3656.203
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	27792.135	+	97.12)
	=	298,811

Total Liabilities	=	Total Assets (Q: Dec. 2024 )	-	Total Equity (Q: Dec. 2024 )
	=	583388.834	-	284578.238
	=	298,811

Daewon Pharmaceutical Co Total Liabilities Related Terms

Thank you for viewing the detailed overview of Daewon Pharmaceutical Co's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Daewon Pharmaceutical Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Daewon Pharmaceutical Co Ltd (XKRX:003220) » Definitions » Total Liabilities

Traded in Other Exchanges

N/A

Address

229-3 Yongdap-dong, Seongdong-gu, Seoul, KOR, 133-850

Website

https://www.daewonpharm.com

Daewon Pharmaceutical Co Ltd is active in the healthcare sector in Korea. Its main business involves antipyretics, respiratory drugs, cardiovascular drugs, and neuromuscular drugs. It also produces a range of health foods such as multivitamins. The company operates on a global basis.

Daewon Pharmaceutical Co Headlines

No Headlines